Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of clinical-stage, small molecule product candidates for central nervous system disorders.
Website: vandapharma.com



Growth: Good revenue growth rate 16.7%, there is acceleration compared to average historical growth rates -3.8%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -56.6%. On average the margin is decreasing steadily. Gross margin is high, +94.8%. In the last quarter the company beat the estimated EPS, +50.0%. The company was ahead of estimated EPS in 25% of quarters (showing a gain of -$0.04 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -18.1% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 130.2% higher than minimum and 11.8% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -1.2x by EV / Sales multiple

Key Financials (Download financials)

Ticker: VNDA
Share price, USD:  (0.0%)7.78
year average price 5.13  


year start price 4.80 2025-02-08

min close price 3.92 2025-05-14

max close price 8.82 2025-12-31

current price 7.78 2026-02-07
Common stocks: 59 091 478

Dividend Yield:  0.0%
EV / Sales: 0.8x
Margin (EBITDA LTM / Revenue): -56.6%
Fundamental value created in LTM:
Market Cap ($m): 460
Net Debt ($m): -288
EV (Enterprise Value): 172
Price to Book: 1.0x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-02-03globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA

2026-01-15seekingalpha.com

Vanda Pharmaceuticals Inc. (VNDA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2026-01-13globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA

2026-01-13zacks.com

Vanda (VNDA) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

2026-01-01seekingalpha.com

Vanda's 2026 Catalyst Run With Nereus Launch And Bysanti PDUFA In Focus

2025-12-31zacks.com

VNDA Obtains FDA Nod for Motion Sickness Drug, Stock Gains

2025-12-30reuters.com

US FDA approves Vanda Pharmaceuticals' motion sickness drug

2025-12-30prnewswire.com

Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness

2025-12-26schaeffersresearch.com

Vanda Pharmaceuticals Stock Rallies on FDA Filing

2025-11-30fool.com

Should You Invest in This Under-the-Radar Weight Loss Stock?
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol VNDA VNDA VNDA VNDA VNDA VNDA VNDA VNDA VNDA VNDA VNDA VNDA VNDA VNDA
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-10-30 2025-07-31 2024-11-07 2024-08-01 2024-05-09 2023-11-09 2023-07-28 2023-05-03 2022-11-03
acceptedDate 2025-10-30 07:23:10 2025-07-31 08:57:58 2025-02-14 16:32:17 2024-11-07 07:07:48 2024-08-01 07:01:35 2024-05-09 07:07:02 2024-02-08 07:19:14 2023-11-09 07:04:34 2023-07-28 07:01:14 2023-05-03 16:55:25 2023-02-09 07:02:38 2022-11-03 07:02:55 2022-02-24 07:02:35 2021-02-11 07:04:13
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 56M 53M 199M 48M 50M 47M 193M 39M 46M 62M 254M 65M 269M 248M
costOfRevenue 3M 4M 11M 3M 4M 5M 15M 3M 3M 5M 24M 6M 26M 23M
grossProfit 53M 48M 187M 45M 46M 42M 178M 36M 43M 58M 230M 59M 243M 225M
grossProfitRatio 0.947 0.915 0.946 0.911 0.885 0.921 0.924 0.924 0.903
researchAndDevelopmentExpenses 23M 22M 74M 17M 17M 21M 77M 17M 17M 19M 86M 25M 75M 56M
generalAndAdministrativeExpenses 0 0 145M 0 0 0 112M 0 0 0 134M 0 117M 128M
sellingAndMarketingExpenses 0 0 2M 0 0 0 500 000 0 0 0 3M 0 7M 13M
sellingGeneralAndAdministrativeExpenses 60M 65M 146M 38M 39M 30M 113M 25M 28M 36M 136M 30M 124M 141M
otherExpenses 2M 0 7M 2M 5M 5M 2M 6M 5M 379 000 2M 379 000 1M 1M
operatingExpenses 85M 87M 228M 56M 56M 51M 192M 42M 45M 56M 224M 55M 201M 198M
costAndExpenses 88M 91M 239M 59M 61M 57M 207M 45M 49M 60M 248M 61M 227M 221M
interestIncome 0 0 0 0 0 0 0 6M 0 0 0 0 199 000 4M
interestExpense 0 0 0 0 0 0 0 0 0 -4M 0 -2M 0 0
depreciationAndAmortization 2M 2M 8M 2M 2M 2M 3M 380 000 378 000 670 000 3M 379 000 3M 3M
ebitda -29M -33M -33M -9M -8M -7M -11M -6M -2M 3M 9M 4M 45M 35M
ebitdaratio -0.52 -0.625 -0.19 -0.162 -0.148 -0.145 -0.054 0.043 0.066
operatingIncome -31M -39M -41M -11M -10M -9M -14M -6M -3M 2M 6M 4M 42M 27M
operatingIncomeRatio -0.556 -0.732 -0.231 -0.201 -0.195 -0.154 -0.062 0.032 0.06
totalOtherIncomeExpensesNet 3M 4M 18M 5M 5M 5M 20M 6M 5M 4M 5M 2M 199 000 4M
incomeBeforeTax -28M -35M -23M -6M -6M -5M 6M -120 000 3M 6M 11M 5M 42M 32M
incomeBeforeTaxRatio -0.505 -0.663 -0.131 -0.109 -0.098 -0.003 0.056 0.088 0.084
incomeTaxExpense -6M -8M -4M -920 000 -998 000 -518 000 4M -257 000 1M 2M 5M 2M 9M 8M
netIncome -23M -27M -19M -5M -5M -4M 3M 137 000 2M 3M 6M 3M 33M 23M
netIncomeRatio -0.401 -0.517 -0.112 -0.09 -0.087 0.004 0.033 0.052 0.05
eps -0.38 -0.46 -0.32 -0.091 -0.078 -0.072 0.044 0.002 0.03 0.057 0.11 0.06 0.6 0.43
epsdiluted -0.38 -0.46 -0.091 -0.078 -0.072 0.002 0.03 0.057 0.06
weightedAverageShsOut 59M 59M 58M 58M 58M 58M 57M 58M 57M 57M 56M 57M 56M 54M
weightedAverageShsOutDil 59M 59M 58M 58M 58M 58M 58M 58M 58M 57M 57M 57M 57M 55M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-14 2024-02-08 2023-02-09 2022-02-24 2021-02-11
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 0 0 0 199 000 4M
ebit -41M -14M 6M 42M 32M
nonOperatingIncomeExcludingInterest 0 0 0 0 -4M
netIncomeFromContinuingOperations -19M 3M 6M 33M 23M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -19M 3M 6M 33M 23M
epsDiluted -0.32 0.044 0.11 0.58 0.42

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol VNDA VNDA VNDA VNDA VNDA VNDA VNDA VNDA VNDA VNDA VNDA VNDA VNDA VNDA
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-10-30 2025-07-31 2024-11-07 2024-08-01 2024-05-09 2023-11-09 2023-07-28 2023-05-03 2022-11-03
acceptedDate 2025-10-30 07:23:10 2025-07-31 08:57:58 2025-02-14 16:32:17 2024-11-07 07:07:48 2024-08-01 07:01:35 2024-05-09 07:07:02 2024-02-08 07:19:14 2023-11-09 07:04:34 2023-07-28 07:01:14 2023-05-03 16:55:25 2023-02-09 07:02:38 2022-11-03 07:02:55 2022-02-24 07:02:35 2021-02-11 07:04:13
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 70M 81M 102M 100M 103M 125M 136M 183M 150M 354M 135M 49M 52M 61M
shortTermInvestments 224M 245M 272M 276M 285M 269M 252M 307M 339M 147M 332M 405M 381M 307M
cashAndShortTermInvestments 294M 326M 375M 376M 388M 394M 388M 490M 489M 501M 467M 455M 433M 368M
netReceivables 51M 45M 47M 43M 42M 37M 34M 29M 34M 25M 34M 29M 32M 30M
inventory 2M 2M 2M 2M 1M 2M 1M 1M 1M 1M 1M 2M 1M 1M
otherCurrentAssets 21M 22M 15M 12M 8M 7M 9M 16M 9M 7M 18M 21M 0 0
totalCurrentAssets 367M 395M 439M 432M 439M 439M 433M 537M 534M 534M 519M 507M 478M 409M
propertyPlantEquipmentNet 12M 12M 13M 8M 9M 9M 9M 10M 10M 10M 11M 11M 12M 15M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 109M 111M 114M 116M 118M 119M 121M 17M 18M 18M 19M 19M 20M 22M
goodwillAndIntangibleAssets 109M 111M 114M 116M 118M 119M 121M 17M 18M 18M 19M 19M 20M 22M
longTermInvestments 0 0 0 0 469 000 469 000 0 469 000 0 0 0 0 0 0
taxAssets 103M 97M 81M 79M 77M 75M 75M 68M 70M 72M 74M 75M 75M 82M
otherNonCurrentAssets 10M 10M 9M 9M 9M 9M 10M 10M 10M 10M 11M 10M 8M 7M
totalNonCurrentAssets 234M 230M 217M 213M 212M 213M 215M 105M 108M 111M 115M 115M 115M 124M
otherAssets 0 0 0 0 1 0 0 0 0 0 0 0 0 0
totalAssets 601M 625M 656M 645M 651M 653M 648M 642M 642M 645M 634M 622M 594M 533M
accountPayables 0 2M 3M 6M 2M 7M 7M 3M 2M 4M 13M 13M 925 000 1M
shortTermDebt 0 5M 0 2M 2M 2M 0 2M 2M 2M 0 2M 0 0
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 0 54M 0 0 -6M -5M 0 0 0 0 0
otherCurrentLiabilities 118M 115M 69M 81M 89M 84M 69M 85M 87M 88M 34M 77M 28M 45M
totalCurrentLiabilities 118M 121M 100M 89M 94M 93M 88M 85M 87M 94M 91M 93M 74M 66M
longTermDebt 6M 7M 0 5M 6M 7M 0 7M 8M 8M 0 9M 0 0
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 11M 10M 10M 9M 9M 9M 9M 6M 6M 7M 7M -2M 4M 3M
totalNonCurrentLiabilities 17M 17M 18M 15M 15M 15M 16M 14M 14M 15M 16M 14M 14M 14M
otherLiabilities 0 0 0 0 0 1 0 0 0 0 0 0 0 0
capitalLeaseObligations 0 12M 12M 8M 8M 7M 9M 7M 8M 11M 11M 9M 12M 14M
totalLiabilities 135M 138M 118M 104M 109M 109M 104M 99M 102M 109M 107M 106M 89M 80M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 59 000 59 000 58 000 58 000 58 000 58 000 58 000 58 000 57 000 57 000 57 000 57 000 56 000 55 000
retainedEarnings -254M -231M -174M -169M -164M -160M -155M -153M -153M -155M -158M -165M -164M -197M
accumulatedOtherComprehensiveIncomeLoss 540 000 396 000 74 000 702 000 -330 000 -383 000 -30 000 -967 000 -865 000 -255 000 -1M -1M -175 000 239 000
othertotalStockholdersEquity 719M 717M 710M 707M 704M 697M 694M 691M 682M
totalStockholdersEquity 466M 486M 539M 541M 543M 544M 545M 543M 540M 536M 527M 516M 505M 453M
totalEquity 466M 486M 539M 541M 543M 544M 545M 543M 540M 536M 527M 516M 505M 453M
totalLiabilitiesAndStockholdersEquity 601M 625M 645M 651M 653M 642M 642M 645M 622M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 601M 625M 656M 645M 651M 653M 648M 642M 642M 645M 634M 622M 594M 533M
totalInvestments 224M 245M 272M 276M 285M 269M 252M 307M 339M 147M 332M 405M 381M 307M
totalDebt 6M 12M 12M 8M 8M 9M 9M 7M 8M 11M 11M 9M 12M 14M
netDebt -64M -69M -90M -93M -95M -116M -126M -176M -142M -343M -124M -40M -40M -47M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-14 2024-02-08 2023-02-09 2022-02-24 2021-02-11
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 47M 34M 34M 32M 30M
otherReceivables 0 0 0 0 0
prepaids 0 0 0 12M 10M
totalPayables 26M 10M 36M 26M 18M
otherPayables 23M 2M 24M 25M 17M
accruedExpenses 0 6M 19M 19M 350 000
capitalLeaseObligationsCurrent 4M 2M 2M 2M 2M
capitalLeaseObligationsNonCurrent 8M 7M 9M 10M 11M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 713M 700M 686M 669M 650M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol VNDA VNDA VNDA VNDA VNDA VNDA VNDA VNDA VNDA VNDA VNDA VNDA VNDA VNDA
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-10-30 2025-07-31 2024-11-07 2024-08-01 2024-05-09 2023-11-09 2023-07-28 2023-05-03 2022-11-03
acceptedDate 2025-10-30 07:23:10 2025-07-31 08:57:58 2025-02-14 16:32:17 2024-11-07 07:07:48 2024-08-01 07:01:35 2024-05-09 07:07:02 2024-02-08 07:19:14 2023-11-09 07:04:34 2023-07-28 07:01:14 2023-05-03 16:55:25 2023-02-09 07:02:38 2022-11-03 07:02:55 2022-02-24 07:02:35 2021-02-11 07:04:13
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome -23M -27M -19M -5M -5M -4M 3M 137 000 2M 3M 6M 3M 33M 23M
depreciationAndAmortization 2M -3M 8M -9M 2M 2M 3M 580 000 602 000 670 000 3M 678 000 3M 3M
deferredIncomeTax -6M -8M -6M -3M -1M -246 000 -1M 3M 1M 2M 1M -2M 7M 6M
stockBasedCompensation 2M 2M 12M 3M 3M 4M 14M 3M 3M 4M 16M 4M 15M 13M
changeInWorkingCapital -8M 15M -7M -2M -5M 7M -747 000 -7M -19M 22M 6M 7M 3M 4M
accountsReceivables -6M -353 000 -13M -830 000 -5M -3M -707 000 4M -9M 9M -1M -593 000 -2M -4M
inventory 32 000 -368 000 -29 000 -214 000 263 000 29 000 -771 000 -554 000 136 000 74 000 -4M -2M -2M -3M
accountsPayables 0 11M 2M -469 000 3M 1M -11M -280 000 -3M -11M 12M 1M 3M 4M
otherWorkingCapital -3M 5M 5M -852 000 -3M 8M 12M -10M -7M 24M -151 000 8M 4M 7M
otherNonCashItems 895 000 5M -4M 2M 7M 9M -5M -2M -1M -524 000 -507 000 -521 000 3M 2M
netCashProvidedByOperatingActivities -32M -15M -16M -15M -7M 8M 13M -2M -13M 32M 32M 13M 64M 52M
investmentsInPropertyPlantAndEquipment -161 000 -299 000 -490 000 -161 000 -108 000 -7000 -383 000 -24 000 -55 000 -51 000 -679 000 -148 000 -552 000 -2M
acquisitionsNet 0 0 -4M 4M -2M -3M -101M -35M 0 655 000 0 0 0 0
purchasesOfInvestments -14M -53M -365M -84M -113M -76M -513M -47M -248M -163M -349M -169M -420M -347M
salesMaturitiesOfInvestments 36M 38M 352M 96M 99M 61M 602M 82M 57M 350M 400M 147M 344M 307M
otherInvestingActivites 0 0 -4M -2M -3M 35M 0 -655 000 0
netCashUsedForInvestingActivites 21M -15M 12M -15M -18M 35M -191M 187M -22M
debtRepayment -517 000 -425 000 0 0 0 0 0 0 0
commonStockIssued 0 0 0 0 0 0 0 0 0
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 0 0 0 0 0 0 0 0 4000
netCashUsedProvidedByFinancingActivities -517 000 -425 000 0 0 0 0 0 0 4000
effectOfForexChangesOnCash -180 000 134 000 -163 000 68 000 -15 000 -14 000 47 000 -122 000 -26 000 45 000 315 000 60 000 -85 000 106 000
netChangeInCash -11M -31M -34M -2M -22M -11M 792 000 33M -204M 219M 83M -9M -9M 16M
cashAtEndOfPeriod 70M 81M 103M 100M 103M 125M 136M 184M 151M 355M 135M 50M 52M 61M
cashAtBeginningOfPeriod 81M 112M 136M 103M 125M 136M 135M 151M 355M 135M 52M 59M 61M 45M
operatingCashFlow -32M -15M -16M -15M -7M 8M 13M -2M -13M 32M 32M 13M 64M 52M
capitalExpenditure -161 000 -299 000 -490 000 -161 000 -108 000 -7000 -383 000 -24 000 -55 000 -51 000 -679 000 -148 000 -552 000 -2M
freeCashFlow -32M -16M -16M -15M -7M 8M 12M -2M -13M 32M 31M 13M 64M 50M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-14 2024-02-08 2023-02-09 2022-02-24 2021-02-11
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 0 0 0 0
netCashProvidedByInvestingActivities -17M -12M 50M -77M -41M
netDebtIssuance -155 000 0 0 0 0
longTermNetDebtIssuance -155 000 0 0 0 0
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 0 0 734 000 4M 6M
netCommonStockIssuance 0 0 734 000 4M 6M
commonStockIssuance 0 0 734 000 4M 6M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 0 0 0 0 0
netCashProvidedByFinancingActivities -155 000 0 734 000 4M 6M
incomeTaxesPaid 0 0 0 0 0
interestPaid 0 0 0 0 0

Earning call transcript

2025 q3
2025-10-29 ET (fiscal 2025 q3)
2025 q2
2025-07-31 ET (fiscal 2025 q2)
2025 q1
2025-05-07 ET (fiscal 2025 q1)
2024 q4
2025-02-13 ET (fiscal 2024 q4)
2024 q3
2024-11-06 ET (fiscal 2024 q3)
2024 q2
2024-08-02 ET (fiscal 2024 q2)
2024 q1
2024-05-08 ET (fiscal 2024 q1)
2023 q4
2024-02-07 ET (fiscal 2023 q4)
2023 q3
2023-11-08 ET (fiscal 2023 q3)
2023 q2
2023-07-27 ET (fiscal 2023 q2)
2023 q1
2023-05-03 ET (fiscal 2023 q1)
2022 q4
2023-02-08 ET (fiscal 2022 q4)
2022 q3
2022-11-02 ET (fiscal 2022 q3)
2022 q2
2022-08-03 ET (fiscal 2022 q2)
2022 q1
2022-05-05 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 8
2025-10-29 20:08 ET
Vanda Pharmaceuticals reported for 2025 q3
SEC form 8
2025-10-29 20:08 ET
Vanda Pharmaceuticals published news for 2025 q3
SEC form 10
2025-07-31 12:57 ET
Vanda Pharmaceuticals reported for 2025 q2
SEC form 8
2025-07-31 11:34 ET
Vanda Pharmaceuticals published news for 2025 q2
SEC form 8
2025-07-31 11:34 ET
Vanda Pharmaceuticals published news for 2025 q2
SEC form 10
2025-05-08 00:00 ET
Vanda Pharmaceuticals published news for 2025 q1
SEC form 8
2025-05-07 20:07 ET
Vanda Pharmaceuticals published news for 2025 q1
SEC form 8
2025-05-07 20:07 ET
Vanda Pharmaceuticals reported for 2025 q1
SEC form 10
2025-02-14 16:32 ET
Vanda Pharmaceuticals reported for 2024 q4
SEC form 10
2025-02-14 00:00 ET
Vanda Pharmaceuticals published news for 2024 q4
SEC form 8
2025-02-13 16:08 ET
Vanda Pharmaceuticals published news for 2024 q4
SEC form 8
2025-02-13 16:08 ET
Vanda Pharmaceuticals published news for 2024 q4
SEC form 10
2024-11-07 07:07 ET
Vanda Pharmaceuticals published news for 2024 q3
SEC form 8
2024-11-06 16:16 ET
Vanda Pharmaceuticals published news for 2024 q3
SEC form 8
2024-11-06 16:16 ET
Vanda Pharmaceuticals published news for 2024 q3
SEC form 10
2024-08-01 07:01 ET
Vanda Pharmaceuticals published news for 2024 q2
SEC form 10
2024-08-01 00:00 ET
Vanda Pharmaceuticals published news for 2024 q2
SEC form 8
2024-07-31 16:05 ET
Vanda Pharmaceuticals published news for 2024 q2
SEC form 8
2024-07-31 16:05 ET
Vanda Pharmaceuticals reported for 2024 q2
SEC form 10
2024-05-09 00:00 ET
Vanda Pharmaceuticals reported for 2024 q1
SEC form 8
2024-05-08 00:00 ET
Vanda Pharmaceuticals published news for 2024 q1
SEC form 8
2024-05-08 00:00 ET
Vanda Pharmaceuticals published news for 2024 q1
SEC form 10
2024-02-08 00:00 ET
Vanda Pharmaceuticals reported for 2023 q4
SEC form 8
2024-02-07 00:00 ET
Vanda Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-07 00:00 ET
Vanda Pharmaceuticals published news for 2023 q4
SEC form 10
2023-11-09 07:04 ET
Vanda Pharmaceuticals published news for 2023 q3
SEC form 10
2023-11-09 00:00 ET
Vanda Pharmaceuticals published news for 2023 q3
SEC form 8
2023-11-08 16:05 ET
Vanda Pharmaceuticals reported for 2023 q3
SEC form 10
2023-07-28 07:01 ET
Vanda Pharmaceuticals published news for 2023 q2
SEC form 10
2023-07-28 00:00 ET
Vanda Pharmaceuticals published news for 2023 q2
SEC form 6
2023-07-27 16:06 ET
Vanda Pharmaceuticals reported for 2023 q2
SEC form 8
2023-07-27 00:00 ET
Vanda Pharmaceuticals published news for 2023 q2
SEC form 6
2023-06-08 16:40 ET
Vanda Pharmaceuticals published news for 2023 q1
SEC form 10
2023-05-03 00:00 ET
Vanda Pharmaceuticals published news for 2023 q1
SEC form 8
2023-05-03 00:00 ET
Vanda Pharmaceuticals published news for 2023 q1
SEC form 6
2023-03-17 07:05 ET
Vanda Pharmaceuticals published news for 2022 q4
SEC form 6
2023-03-13 09:25 ET
Vanda Pharmaceuticals published news for 2022 q4
SEC form 6
2023-02-17 16:31 ET
Vanda Pharmaceuticals published news for 2022 q4
SEC form 10
2023-02-09 07:02 ET
Vanda Pharmaceuticals reported for 2022 q4
SEC form 10
2023-02-09 00:00 ET
Vanda Pharmaceuticals reported for 2022 q4
SEC form 6
2023-02-08 16:09 ET
Vanda Pharmaceuticals published news for 2022 q4
SEC form 8
2023-02-08 00:00 ET
Vanda Pharmaceuticals reported for 2022 q4
SEC form 6
2022-12-22 19:22 ET
Vanda Pharmaceuticals published news for 2022 q3
SEC form 6
2022-12-16 17:16 ET
Vanda Pharmaceuticals published news for 2022 q3
SEC form 6
2022-12-14 06:06 ET
Vanda Pharmaceuticals published news for 2022 q3
SEC form 10
2022-11-03 07:02 ET
Vanda Pharmaceuticals reported for 2022 q3
SEC form 10
2022-11-03 00:00 ET
Vanda Pharmaceuticals reported for 2022 q3
SEC form 6
2022-11-02 16:08 ET
Vanda Pharmaceuticals published news for 2022 q3
SEC form 8
2022-11-02 00:00 ET
Vanda Pharmaceuticals reported for 2022 q3
SEC form 10
2022-08-04 07:02 ET
Vanda Pharmaceuticals reported for 2022 q2
SEC form 10
2022-08-04 00:00 ET
Vanda Pharmaceuticals reported for 2022 q2
SEC form 6
2022-08-03 16:12 ET
Vanda Pharmaceuticals published news for 2022 q2
SEC form 8
2022-08-03 00:00 ET
Vanda Pharmaceuticals reported for 2022 q2
SEC form 6
2022-06-16 16:16 ET
Vanda Pharmaceuticals published news for 2022 q1
SEC form 10
2022-05-06 07:03 ET
Vanda Pharmaceuticals reported for 2022 q1
SEC form 10
2022-05-06 00:00 ET
Vanda Pharmaceuticals reported for 2022 q1
SEC form 6
2022-05-05 16:21 ET
Vanda Pharmaceuticals published news for 2022 q1
SEC form 8
2022-05-05 00:00 ET
Vanda Pharmaceuticals reported for 2022 q1
SEC form 6
2022-04-25 16:32 ET
Vanda Pharmaceuticals published news for 2022 q1
SEC form 6
2022-03-01 16:06 ET
Vanda Pharmaceuticals published news for 2021 q4
SEC form 10
2022-02-24 07:02 ET
Vanda Pharmaceuticals published news for 2021 q4
SEC form 10
2022-02-24 00:00 ET
Vanda Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-23 16:10 ET
Vanda Pharmaceuticals published news for 2021 q4
SEC form 8
2022-02-23 00:00 ET
Vanda Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-04 07:07 ET
Vanda Pharmaceuticals published news for 2021 q4
SEC form 6
2022-01-14 16:05 ET
Vanda Pharmaceuticals published news for 2021 q4
SEC form 10
2021-11-04 07:11 ET
Vanda Pharmaceuticals published news for 2021 q3
SEC form 10
2021-11-04 00:00 ET
Vanda Pharmaceuticals published news for 2021 q3
SEC form 6
2021-11-03 16:08 ET
Vanda Pharmaceuticals published news for 2021 q3
SEC form 8
2021-11-03 00:00 ET
Vanda Pharmaceuticals published news for 2021 q3
SEC form 6
2021-10-08 16:07 ET
Vanda Pharmaceuticals published news for 2021 q3
SEC form 10
2021-07-29 07:02 ET
Vanda Pharmaceuticals published news for 2021 q2
SEC form 10
2021-07-29 00:00 ET
Vanda Pharmaceuticals published news for 2021 q2
SEC form 6
2021-07-28 16:08 ET
Vanda Pharmaceuticals published news for 2021 q2
SEC form 8
2021-07-28 00:00 ET
Vanda Pharmaceuticals published news for 2021 q2
SEC form 6
2021-06-10 17:01 ET
Vanda Pharmaceuticals published news for 2021 q1
SEC form 10
2021-05-06 07:01 ET
Vanda Pharmaceuticals published news for 2021 q1
SEC form 10
2021-05-06 00:00 ET
Vanda Pharmaceuticals published news for 2021 q1
SEC form 6
2021-05-05 16:06 ET
Vanda Pharmaceuticals published news for 2021 q1
SEC form 8
2021-05-05 00:00 ET
Vanda Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-22 07:01 ET
Vanda Pharmaceuticals published news for 2021 q1
SEC form 6
2021-02-25 07:01 ET
Vanda Pharmaceuticals published news for 2020 q4
SEC form 10
2021-02-11 07:04 ET
Vanda Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-10 16:08 ET
Vanda Pharmaceuticals published news for 2020 q4
SEC form 6
2020-12-02 07:02 ET
Vanda Pharmaceuticals published news for 2020 q3
SEC form 10
2020-10-29 07:01 ET
Vanda Pharmaceuticals published news for 2020 q3
SEC form 6
2020-10-28 16:05 ET
Vanda Pharmaceuticals published news for 2020 q3